2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Other Pathogens, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6242 Frontline treatment and consolidation strategies and associated outcomes in primary central nervous system lymphoma: A large US real-world study

Anthony Proli, PharmD, Farhad Khan, MSPH2, Yunzhi Qian, PhD3, Christoph Buhl, MD4, Ahmed Sawas, MD5
1 Flatiron Health, New York, New York, United States
2 Flatiron Health, New York, New York, United States
3 Flatiron Health, Durham, North Carolina, United States
4 Flatiron Health GmbH, Berlin, Germany
5 Flatiron Health, New York, New York, United States

Introduction: Primary central nervous system lymphoma (PCNSL) is a rare subtype of B-cell lymphoma involving the brain, leptomeninges, spinal cord, or eyes. Due to its rarity, there is high variability in treatment options with no clear standard of care for either front-line therapy or consolidation. Also, there has been little research performed describing how patients are treated in the real world and assessing their associated outcomes. The objective of this study was to describe clinical characteristics, treatment patterns, real-world progression free survival (rwPFS), and real-world overall survival (rwOS) among patients diagnosed with PCNSL in a large United States (US)-based oncology dataset.

Methods: This longitudinal, retrospective cohort study used patient-level data from >82,000 patients with LBCL in the US-based, electronic health record-derived, deidentified Flatiron Health Research Database and included patients with a diagnosis of PCNSL between January 1, 2011 and April 30, 2026. Baseline demographics, clinical characteristics, and treatment patterns were summarized using descriptive statistics. rwOS and rwPFS were estimated for the first-line(1L) treated population using Kaplan-Meier methods, indexed to treatment initiation. Patients were censored at their last documented clinical activity or the data cutoff, as applicable.

Results: A total of 2792 patients were identified as being diagnosed with PCNSL during the observation period, with 27% diagnosed from 2011-2015, 28% from 2016-2019, and 44% from 2020-2026. Overall, 51% were female with a median age of 67 (IQR, 58-74), and 42.2% of patients were less than age 65. The majority of patients were white (70%), non-hispanic (74%), and 60% had a socioeconomic status index ≳3. The majority of patients were treated in community-based practices (57%) compared with academic practices (37%). Of the 2792 patients included, a total of 2516 (90%) had documentation of at least 1 line of therapy (1L), with 1307 (47%) having only 1L, 733 (26%) with 2L, and 476 (17%) with 3L or more. The 1L treatments were high-dose methotrexate (HD-MTX) ± rituximab (R) in 1020 (41%), HD-MTX + R + other chemotherapy in 299 (12%), 238 patients (9.5%) received R-MPV, 200 patients (7.9%) received a clinical study drug, 86 patients (3.4%) received the MATRix regimen, and 618 (25%) received other chemotherapy. For consolidation treatment, 380 (15%) received radiation, 237 (9.4%) received hematopoietic cell transplant (HCT), and 197 (7.9%) received high-dose cytarabine ± etoposide. These consolidation categories were not mutually exclusive.

Among patients treated in 1L, median rwPFS and rwOS were 25.4 months (95% CI, 21.88-29.11) and 60.45 months (95% CI, 53.82-65.38), respectively. Median rwPFS and rwOS were 19.55 months (95% CI, 16.23-25.33) and 60.45 months (95% CI, 46.52-69.55) with less-intensive induction (HD-MTX ± R), compared with 29.73 months (95% CI, 22.28-38.08) and 66.76 months (95% CI, 53.82-96.46) with intensive induction (HD-MTX + R + additional chemotherapy, R-MPV, or MATRiX), respectively. The median rwOS observed with different consolidation strategies was 133.98 mo with consolidative HCT, 44.71 mo with radiation, 106.87 mo with high-dose cytarabine ± etoposide, and 53.06 mo without documented consolidation. Intensive induction and HCT were more common in patients aged <65 years and in academic practices.

Conclusions: This large, mainly community-based retrospective cohort study demonstrated substantial heterogeneity in treatment for PCNSL. Patients predominantly received a HD-MTX based 1L treatment, and few patients received consolidation therapy with radiation, HCT, or chemotherapy. rwPFS and rwOS were observed to be longer in patients receiving intensive induction compared to less-intensive induction, as well as in patients receiving HCT compared to alternative consolidation strategies. This could be due to the intensity of the treatments received or those patients being younger and more commonly being treated in academic practices. These findings provide a contemporary benchmark for PCNSL treatment patterns and outcomes across US oncology practices. Further research regarding factors that are associated with treatment selection and outcomes could inform risk stratification and clinical decision making in this difficult to treat population.

Anthony Proli, PharmD: Pfizer - Current equity holder in publicly-traded company; Roche - Current equity holder in publicly-traded company; Flatiron Health, Inc. - Research Funding; Flatiron Health, Inc. - Current Employment